Stock A253840 SUGENTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sugentech Inc.

Equities

A253840

KR7253840003

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
5,480 KRW +1.86% Intraday chart for Sugentech Inc. -3.01% -29.29%
2023 Tranche Update on Sugentech Inc.'s Equity Buyback Plan announced on March 29, 2023. CI
2023 Tranche Update on Sugentech Inc.'s Equity Buyback Plan announced on March 29, 2023. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 146,253 70,835 310,488 216,446 165,128 118,431
Enterprise Value (EV) 1 143,620 50,066 278,429 124,955 71,561 66,917
P/E ratio -2.2 x -7.08 x -6.92 x 6.89 x 6.73 x -13.6 x
Yield - - - - 1.48% -
Capitalization / Revenue 26.8 x 18.4 x 7.51 x 2.8 x 1.63 x 16.6 x
EV / Revenue 26.4 x 13 x 6.73 x 1.62 x 0.71 x 9.38 x
EV / EBITDA -35.1 x -7.77 x 11.9 x 3.45 x 2.5 x -3.72 x
EV / FCF - 27,483,985 x -47,267,788 x 3,920,252 x -28,742,142 x -3,116,853 x
FCF Yield - 0% -0% 0% -0% -0%
Price to Book 9.5 x 2.91 x 4.92 x 2.15 x 1.17 x 1.05 x
Nbr of stocks (in thousands) 11,426 12,926 15,295 15,460 16,269 15,281
Reference price 2 12,800 5,480 20,300 14,000 10,150 7,750
Announcement Date 3/19/20 3/19/20 3/17/21 3/23/22 3/21/23 3/20/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 5,449 3,845 41,352 77,201 101,399 7,132
EBITDA 1 -4,090 -6,444 23,395 36,209 28,587 -17,975
EBIT 1 -4,603 -7,069 22,512 34,814 24,971 -22,758
Operating Margin -84.48% -183.85% 54.44% 45.09% 24.63% -319.08%
Earnings before Tax (EBT) 1 -40,930 -9,562 -40,817 43,310 32,322 -18,722
Net income 1 -40,915 -9,561 -41,018 36,152 26,717 -17,238
Net margin -750.91% -248.66% -99.19% 46.83% 26.35% -241.69%
EPS 2 -5,807 -774.0 -2,935 2,033 1,509 -570.4
Free Cash Flow - 1,822 -5,890 31,874 -2,490 -21,469
FCF margin - 47.38% -14.24% 41.29% -2.46% -301.02%
FCF Conversion (EBITDA) - - - 88.03% - -
FCF Conversion (Net income) - - - 88.17% - -
Dividend per Share - - - - 150.0 -
Announcement Date 3/19/20 3/19/20 3/17/21 3/23/22 3/21/23 3/20/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 2,633 20,769 32,059 91,491 93,567 51,514
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - 1,822 -5,890 31,874 -2,490 -21,469
ROE (net income / shareholders' equity) - -46.3% -92.3% 41.8% 20.9% -13.5%
ROA (Net income/ Total Assets) - -12.7% 23.9% 19.1% 9.49% -9.28%
Assets 1 - 75,517 -171,824 189,426 281,485 185,719
Book Value Per Share 2 1,347 1,880 4,126 6,514 8,641 7,361
Cash Flow per Share 2 99.10 204.0 1,092 4,276 3,201 1,458
Capex 1 1,853 1,856 4,387 5,227 15,848 5,651
Capex / Sales 34% 48.27% 10.61% 6.77% 15.63% 79.23%
Announcement Date 3/19/20 3/19/20 3/17/21 3/23/22 3/21/23 3/20/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
SUGENTECH INC. Stock Sugentech Inc.
-29.29% 60.83M
BIOMÉRIEUX Stock bioMérieux
+0.99% 12.95B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-7.57% 7.84B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+2.04% 5.5B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
+0.02% 4.61B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+7.74% 4.61B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-48.25% 3.4B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+9.21% 2.66B
VITROLIFE AB Stock Vitrolife AB
-14.59% 2.08B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+2.51% 1.79B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. A253840 Stock
  4. Financials Sugentech Inc.